Connect with us

Health

History Isn’t Entirely Repeating Itself in Covid’s Aftermath

Published

on

History Isn’t Entirely Repeating Itself in Covid’s Aftermath

Five years after Covid-19 shut down activities all over the world, medical historians sometimes struggle to place the pandemic in context.

What, they are asking, should this ongoing viral threat be compared with?

Is Covid like the 1918 flu, terrifying when it was raging but soon relegated to the status of a long-ago nightmare?

Is it like polio, vanquished but leaving in its wake an injured but mostly unseen group of people who suffer long-term health consequences?

Or is it unique in the way it has spawned a widespread rejection of public health advice and science itself, attitudes that some fear may come to haunt the nation when the next major illness arises?

Advertisement

Some historians say it is all of the above, which makes Covid stand out in the annals of pandemics.


In many ways, historians say, the Covid pandemic — which the World Health Organization declared on March 11, 2020 reminds them of the 1918 flu. Both were terrifying, killing substantial percentages of the population, unlike, say, polio or Ebola or H.I.V., terrible as those illnesses were.

The 1918 flu killed 675,000 people out of a U.S. population of 103 million, or 65 out of every 10,000. Covid has so far killed about 1,135,000 Americans out of a population of 331.5 million, or 34 out of every 10,000.

Both pandemics dominated the news every day while they raged. And both were relegated to the back of most people’s minds as the numbers of infections and deaths fell.

J. Alexander Navarro, a medical historian at the University of Michigan, said that in the fall of 1918, when the nation was in the throes of the deadliest wave of the 1918 flu, “newspapers were chock-full of stories about influenza, detailing daily case tallies, death tolls, edicts and recommendations issued by officials.”

Advertisement

During the next year, the virus receded. And so did the nation’s attention.

There were no memorials for flu victims, no annual days of remembrance.

“The nation simply moved on,” Dr. Navarro said.

Much the same thing happened with Covid, historians say, although it took longer for the virus’s harshest effects to recede.

Most people live as though the threat is gone, with deaths a tiny fraction of what they once were.

Advertisement

In the week of Feb. 15, 273 Americans died of Covid. In the last week of 2021, 10,476 Americans died from Covid.

Interest in the Covid vaccine has plummeted, too. Now just “a measly 23 percent of adults” have gotten the updated vaccine, Dr. Navarro noted.

Remnants of Covid remain — lasting financial effects, lags in educational achievement, casual dress, Zoom meetings, a desire to work from home. But few think of Covid as they go about their daily lives.

Dora Vargha, a medical historian at the University of Exeter, noted that there had been no ongoing widespread effort to memorialize Covid deaths. Instead, with Covid, “people disappeared into hospitals and never came out.”

Now it is only their friends and families who remember.

Advertisement

Dr. Vargha called that response understandable. People, she said, do not want to be “dragged back” into memories of those Covid years.


But some, like those suffering from long Covid, can’t forget. In that sense, she sees parallels with other pandemics that, unlike the 1918 flu, left a swath of people who were permanently affected.

People who contracted paralytic polio in the 1950s described themselves to Dr. Vargha as “the dinosaurs,” reminders of the time before the vaccine, when the virus was killing or paralyzing children.

Every pandemic has its dinosaurs, she said. They are the Zika babies living with microcephaly. They are the people, often at the margins of society, who develop AIDS.They are the people who contract tuberculosis.

But despite the pleas from those who cannot forget Covid and who seek more research, more empathy, more attention, the more pervasive attitude is, “We don’t need to care anymore,” said Mary Fissell, a historian at Johns Hopkins University.

Advertisement

That sounds so callous, and yet, said Dr. Barron Lerner, a historian at NYU Langone Health, in the world of public health “there are always people who are left behind — damaged or still at risk.”

“It’s hurtful” for people to be shunted aside, Dr. Lerner said. “Their lives are altered. The attention you feel their situation warrants is downplayed.”

But, he added, “on a realistic basis, there are any number of things to study.” Resources are limited, he noted, adding, “it can make sense to move on.”


One aspect of the Covid pandemic, though, is still with the nation, and seems to be part of a new reality: It has markedly changed attitudes toward public health.

Kyle Harper, a historian at the University of Oklahoma, said he would give the biomedical response to Covid an A-plus. “The rollout of vaccines was incredible,” he said.

Advertisement

But, he said, “I would give the social response a C-minus.”

Dr. Lerner had the same thought.

Few medical experts, he said, expected so much resistance to measures like masks, quarantines, social distancing and — when they became available — vaccines and vaccine mandates.

With Covid, he said, “compared to other pandemics, the amount of pushback to standard public health practices was remarkable.”

“That sets Covid apart,” he said. Public health measures that had worked in the past were rejected.

Advertisement

Some of the pushback was reasonable, he said, like objections to wearing masks outdoors. But the spurning of public health measures was widespread and politicized.

Dr. Navarro agreed and said the contrast with 1918 was striking.

“In 1918, there was an abiding respect for science and medicine that seems lacking today,” he said. There were pockets of resistance to measures like masking and avoiding large groups. But for the most part, he said, people complied with public health advice. And compliance was divorced from politics.

World War I also played a role in the messaging, Dr. Navarro said, which may have bolstered adherence.

“Public health orders and recommendations often purposely used the same language that was used to drum up support for the war effort,” Dr. Navarro said. The authorities, for example, asked people “to cover their coughs and sneezes so as not to gas their fellow citizens as the doughboys were being gassed by the Germans.”

Advertisement

Dr. Lerner contrasted the Covid response to the response to the polio vaccine.

The polio vaccine underwent preliminary testing, and then widespread testing, in the 1950s, with broad public acceptance.

With Covid, “faith in the scientific process got lost,” Dr. Lerner said.

That does not bode well for the next pandemic, Dr. Harper said.

“There’s going to be another pandemic,” he said. “And if we have to fight it without public trust, that’s the worst possible response.”

Advertisement

Health

Guava for Weight Loss Is a Real Thing—Here’s the Juicy Truth

Published

on

Guava for Weight Loss Is a Real Thing—Here’s the Juicy Truth


Advertisement





How Guava for Weight Loss Melts Belly Fat Faster




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Single workout cuts cravings, offering new hope for smokers trying to quit

Published

on

Single workout cuts cravings, offering new hope for smokers trying to quit

NEWYou can now listen to Fox News articles!

If you’re trying to quit smoking, try a brisk walk or bike ride to curb your craving for a cigarette.

Researchers found that just one workout can reduce the urge to light up. But the type of exercise you do and how you do it makes a big difference.

High-intensity, aerobic exercise is most effective at reducing people’s cigarette cravings, a review of 59 randomized controlled trials involving more than 9,000 adults found.

FITNESS EXPERT REVEALS SIMPLE RULE TO GET IN SHAPE WITHOUT DREADING THE GYM: ‘JUST MOVE’

Advertisement

“Single-bout exercise reduced acute cravings immediately and up to 30 minutes post-exercise, but not longer-term cravings,” the authors of the study, published in the Journal of Sport and Health Science, reported.

Aerobic exercise is the most effective form of exercise for reducing cravings for cigarettes, researchers found. (iStock)

The research team highlighted other key findings from their study of “exercise-based interventions for smoking cessation.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Exercise training made people between 15% and 21% more likely to abstain from smoking than those who didn’t exercise, the authors found.

Advertisement

Researchers found that exercise curbs people’s cigarette cravings for up to 30 minutes after they stop exercising. (iStock)

Regular exercise also caused smokers to cut back by an average of two cigarettes per day.

In addition to being a free and accessible method for reducing smoking, exercise is also effective at reducing anxiety and stress, which drive many people to smoke.  

CLICK HERE FOR MORE LIFESTYLE STORIES

Advertisement

The authors suggest that because exercise boosts feel-good hormones, such as dopamine, and reduces the stress hormone cortisol, smokers who work out feel less inclined to use nicotine as a brain reward.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Exercise should be integrated into other smoking cessation programs to enhance quit success, the authors concluded.

Exercise releases similar feel-good brain chemicals that people get from cigarettes, researchers suggested. (iStock)

They also noted that none of the trials addressed vaping and recommended that future research target the use of electronic cigarettes.

Advertisement

Continue Reading

Health

Hantavirus Vaccines and Treatments Are in the Pipeline

Published

on

Hantavirus Vaccines and Treatments Are in the Pipeline

The deadly hantavirus outbreak aboard the cruise ship MV Hondius has put the spotlight on a rare pathogen that typically attracts relatively little attention, even from scientists.

There are no targeted treatments for hantaviruses, which are typically carried by rodents, and no widely available vaccines. So when passengers began falling ill in the middle of the Atlantic Ocean, doctors and public health experts were limited in what they could offer.

“It’s kind of a wake-up call,” said Dr. Vaithi Arumugaswami, an infectious disease researcher at the University of California, Los Angeles. “Our tool kit is almost empty.”

That’s not for lack of trying. A handful of scientific teams around the world have been working — for decades, in some cases — to develop hantavirus treatments and vaccines. But it has not been easy to find funding or nurture commercial interest in medical interventions for a type of pathogen that does not infect humans often and does not spread easily between people.

“It’s not an airborne, highly contagious viral threat, so it hasn’t been as high a priority for groups trying to prevent pandemics,” said Jay Hooper, a virologist at the United States Army Medical Research Institute of Infectious Diseases.

Advertisement

But there are promising vaccines and treatments in development. And some of them, experts said, could be moved through the pipeline rapidly if hantavirus interventions became a priority.

“I do think there are things that are sitting there on the bench that could be quickly developed,” said Dr. Ronald Nahass, the president of the Infectious Diseases Society of America. “But nothing is ready.”

There are two main types of hantaviruses: Old World viruses, which circulate primarily in Asia and Europe, and New World viruses, which are found in the Americas. The cruise ship outbreak has been linked to a New World virus known as the Andes virus, which is endemic to South America and is the only hantavirus known to spread between people.

There are vaccines that target some of the Old World viruses in Asia, but their efficacy is modest, experts said. And there are no licensed vaccines for the New World viruses, which include the Sin Nombre virus endemic to rodents in the western United States.

But there are some in development. Dr. Hooper and his colleagues have developed a DNA vaccine for the Andes virus, which proved promising in a small phase 1 trial. Under certain dosing regimens, the researchers found, more than 80 percent of participants produced neutralizing antibodies. “It’s pretty amazing,” said Dr. Hooper, who is an inventor on multiple hantavirus vaccine patents owned by the U.S. government. “Getting these kinds of neutralizing antibodies in humans is impressive.”

Advertisement

There were drawbacks, including that the vaccine seemed to require at least three doses. But the vaccine is ready for further development “if there’s a need,” Dr. Hooper said. “We’ve done the science. It’s just other forces that are required to move vaccines forward — markets, government demand.”

Other teams have potential vaccines in earlier stages of development. For instance, Bryce Warner, a hantavirus researcher at the University of Saskatchewan, and his colleagues are exploring a variety of approaches, including a nasal vaccine that they hope might spark a more robust immune response in the airway.

But the research, which is being conducted in hamsters, is still in early stages, and hantavirus vaccine candidates can be challenging to move forward. Scientists lack good large-animal models for hantaviruses, Dr. Warner said, and human cases are rare enough to make trials tricky. “It’s very difficult to conduct a clinical trial when you only have a limited number of cases annually,” he said. “You don’t have the numbers of people to really show a robust effect.”

Currently, the primary treatment for hantavirus infection is supportive care, which may include supplemental oxygen or heart-lung bypass machines. Doctors also sometimes prescribe an existing antiviral drug, called ribavirin, but there is not strong evidence that it is effective for New World viruses, scientists said.

The hunt for new drugs is underway, though. At U.C.L.A., Dr. Arumugaswami and his colleagues found that favipiravir, an antiviral approved to treat influenza in Japan, inhibited the Andes virus in human cells. They also identified several compounds that had broad antiviral activity, blocking hantaviruses as well as other types of viruses, in human organoids, miniature clusters of tissue that mimic the function of organs.

Advertisement

Other teams have been working to develop therapeutic antibody treatments, often working from blood samples collected from hantavirus survivors. “We were able to isolate the natural antibodies that people are making and basically winnow them down and find one that was really good,” said Kartik Chandran, a virologist at the Albert Einstein College of Medicine in New York. “We actually found several.”

When Dr. Chandran and his colleagues tested these antibodies in hamsters, one produced especially encouraging results: It seemed to work against both Old and New World hantaviruses and was effective even when given relatively late in the course of infection, Dr. Chandran said.

(Dr. Chandran is listed as an inventor on patents for hantavirus antibodies.)

Several other teams have also produced antibodies that were broadly effective in small animals, but that is where a number of potential products have stalled, experts said.

“We have a lead drug, and now what we need is someone to pay the money, which would be something like $40 million, to go the next step,” said Dr. James Crowe, director of the Vanderbilt Center for Antibody Therapeutics. “We have neither government nor foundation nor company support to do that. So we’re just waiting to find a partner.”

Advertisement

(Vanderbilt University has applied for patents related to these antibodies; Dr. Crowe is listed as the inventor.)

Experts said that they hoped the current outbreak might help bring attention to a family of often-overlooked viruses.

“Certainly judging by just my inbox and text messages, there’s a renewed interest in these agents, and renewed interest in maybe at least revisiting where they are in the priority list,” Dr. Chandran said.

Whether that interest can be sustained after the virus fades from the headlines remains to be seen, experts acknowledged.

“Raising awareness never hurts,” Dr. Warner said. “We’ll see whether or not it leads to anything tangible, at least in terms of funding and resources for advancing some of these things that are lacking for hantavirus.”

Advertisement
Continue Reading
Advertisement

Trending